Researchers have developed a new model to track inflammation-driven blood clots that can cause complications in sickle cell ...

Dennis T. Ko, M.D. However, a significant proportion of STEMI patients will "fail" to reperfuse following fibrinolytic therapy; indeed, normal coronary blood flow (TIMI flow grade 3) is achieved ...